Objective: Transcription elongation factor 1 (TCERG1) is a nuclear protein consisted of multiple protein structural domains that plays an important role in regulating the transcription, extension, and splicing regulation of RNA polymerase II. However, the prognostic and immunological role of TCERG1 in human cancer remains unknown. In this study, we analyzed the expression of TCERG1 gene in hepatocellular carcinoma (HCC) patients, its clinical significance, and its possible prognostic value by bioinformatics.Methods: RNA sequencing data and clinicopathological characteristics of patients with HCC were collected from TCGA and CCLE databases. The Wilcoxon rank-sum test was used to analyze the expression of TCERG1 in HCC tissues and normal tissues. The protein levels of TCERG1 between normal and liver cancer tissues were analyzed by the Human Protein Atlas Database (HPA) (www.proteinatlas.org). Validation was performed using the Gene Expression Omnibus (GEO) dataset of 167 samples. The expression of TCERG1 in HCC cells were verified by qRT-PCR, and CCK-8, scratch assay and Transwell assay were performed to detect cell proliferation, migration and invasion ability. According to the median value of TCERG1 expression, patients were divided into high and low subgroups. Logistic regression, GSEA enrichment, TME, and single-sample set gene enrichment analysis (ssGSEA) were performed to explore the effects of TCERG1 on liver cancer biological function and immune infiltrates. TCERG1 co-expression networks were studied through the CCLE database and the LinkedOmics database to analyze genes that interact with TCERG1.Results: The expression levels of TCERG1 in HCC patient tissues were significantly higher than in normal tissues. Survival analysis showed that high levels of TCERG1 expression were significantly associated with low survival rates in HCC patients. Multifactorial analysis showed that high TCERG1 expression was an independent risk factor affecting tumor prognosis. This result was also verified in the GEO database. Cellular experiments demonstrated that cell proliferation, migration and invasion were inhibited after silencing of TCERG1 gene expression. Co-expression analysis revealed that CPSF6 and MAML1 expression were positively correlated with TCERG1. GSEA showed that in samples with high TCERG1 expression, relevant signaling pathways associated with cell cycle, apoptosis, pathways in cancer and enriched in known tumors included Wnt signaling pathway, Vegf signaling pathway, Notch signaling pathway, MAPK signaling pathway and MTOR pathways. The expression of TCERG1 was positively correlated with tumor immune infiltrating cells (T helper two cells, T helper cells).Conclusion:TCERG1 gene is highly expressed in hepatocellular carcinoma tissues, which is associated with the poor prognosis of liver cancer, and may be one of the markers for the diagnosis and screening of liver cancer and the prediction of prognosis effect. At the same time, TCERG1 may also become a new target for tumor immunotherapy.

No abstract

No abstract

Background Under physiological conditions, DNA damage and repair are in a dynamic equilibrium. When this equilibrium is disrupted, the cell undergoes pathological changes, eventually the cell becomes cancerous. Ovarian cancer (OC) is a malignant disease with unique genomic characteristics, most of the chemotherapeutic agents currently used in ovarian cancer depend on the balance between damage and repair of DNA (DDR). DDR-related genes have potential value as prognostic indicators for ovarian cancer. Results DDR-related genes can well typing ovarian cancer patients, 16 genes associated with prognosis of ovarian cancer patients (CH25H, CCR7, CACNA1C, SLC4A8, CXCL11, UBD, TRPV4, RPS6KA2, FCGBP, TOMM20L, STX18, PI3, CMBL, ISG20, AKAP12, and PIGS) were screened as risk genes for the construction of ovarian cancer prognostic models. Conclusion Based on DDR-related genes for ovarian cancer typing and studying the prognostic relevance of differential genes between typing on ovarian cancer, 16 genes were screened for predicting poor prognosis of OC. To provide research directions for subsequent drug development and research basis for clinical application.